Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy

被引:0
作者
Xu, Yu [1 ]
Xie, Yang-Mei [2 ]
Sun, Wen-Sha [3 ]
Zi, Rong [2 ]
Lu, Hong-Qiao [2 ]
Xiao, Le [2 ]
Gong, Kun-Mei [2 ]
Guo, Shi-Kui [2 ]
机构
[1] Panzhihua Cent Hosp, Panzhihua, Sichuan, Peoples R China
[2] Kunming Univ Sci & Technol, Affiliated Hosp, Jinbi Rd, Kunming 650500, Yunnan, Peoples R China
[3] Yunnan Univ Tradit Chinese Med, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
关键词
colorectal adenocarcinoma; endoplasmic reticulum stress; risk score; prognostic model;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Endoplasmic reticulum (ER) stress plays a pro-apoptotic role in colorectal adenocarcinoma (COAD). This study aimed to develop a novel ER-stress-related prognostic risk model for COAD and provide support for COAD cohorts with different risk score responses to immune checkpoint inhibitor therapies. Methods: TCGA-COAD and GSE39582 were included in this prospective study. Univariate and multivariate Cox analyses were performed to identify prognostic ER stress-related genes (ERSGs). Accordingly, the immune infiltration landscape and immunotherapy response in different risk groups were assessed. Finally, the expression of prognostic genes in 10 normal and 10 COAD tissue samples was verified using reverse transcription-quantitative polymerase chain reaction. Results: Eight prognostic genes were selected to establish an ERSG-based signature in the training set of the TCGA-COAD cohort. The accuracy of this was confirmed using a testing set of TCGA-COAD and GSE39582 cohorts. Gene set variation analysis indicated that differential functionality in high-low-risk groups was related to immune-related pathways. Corresponding to this, CD36, TIMP1, and PTGIS were significantly associated with 19 immune cells with distinct proportions between the different risk groups, such as central memory CD4T cells and central memory CD8T cells. Moreover, the risk score was considered effective for predicting the clinical response to immunotherapy, and the immunotherapy response was significantly and negatively correlated with the risk score of individuals with COAD. Furthermore, the immune checkpoint inhibitor treatment was less effective in the high-risk group, where the expression levels of PD-L1 and tumor immune dysfunction and exclusion scores in the high-risk group were significantly increased. Finally, the experimental results demonstrated that the expression trends of prognostic genes in clinical samples were consistent with the results from public databases. Conclusion: Our study established a novel risk signature to predict the COAD prognosis of patients and provide theoretical support for the clinical treatment of COAD.
引用
收藏
页数:18
相关论文
共 55 条
[11]   Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook [J].
Garcia, Josep ;
Hurwitz, Herbert, I ;
Sandler, Alan B. ;
Miles, David ;
Coleman, Robert L. ;
Deurloo, Regula ;
Chinot, Olivier L. .
CANCER TREATMENT REVIEWS, 2020, 86
[12]   Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients [J].
Godoy-Ortiz, A. ;
Plata, Y. ;
Alcaide, J. ;
Galeote, A. ;
Pajares, B. ;
Saez, E. ;
Alba, E. ;
Sanchez-Munoz, A. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (07) :922-927
[13]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[14]  
Hirasawa Takeshi, 2018, Tokai J Exp Clin Med, V43, P81
[15]   Prognostic Factors and Local Treatment Modalities of Small-Cell Carcinoma of the Cervix: An Analysis According to the International Federation of Gynecology and Obstetrics Stage [J].
Huang, Ru ;
Gan, Qiyu ;
Cheng, Jingxin .
CANCER MANAGEMENT AND RESEARCH, 2020, 12 :3445-3456
[16]   Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes [J].
Huinen, Zowi R. ;
Huijbers, Elisabeth J. M. ;
van Beijnum, Judy R. ;
Nowak-Sliwinska, Patrycja ;
Griffioen, Arjan W. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (08) :527-540
[17]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[18]  
Iida Tetsuji, 2019, Tokai J Exp Clin Med, V44, P40
[19]   An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study [J].
Li, Ning ;
Wang, Ziyi ;
Yuan, Guangwen ;
Sun, Yangchun ;
Zhang, Rong ;
Li, Xiaoguang ;
Li, Nan ;
Wang, Jing ;
Wu, Lingying .
JOURNAL OF ONCOLOGY, 2020, 2020
[20]   Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses [J].
Lin, Li-mei ;
Lin, Qin ;
Liu, Jun ;
Chu, Ke-xin ;
Huang, Yun-Xia ;
Zhang, Zong-Kai ;
Li, Tao ;
Dai, Ya-Qing ;
Li, Jin-Luan .
CANCER MEDICINE, 2020, 9 (18) :6524-6532